CN106581700A - Novel HER2-targeting polypeptide radioactive medicine and preparation method and application thereof - Google Patents
Novel HER2-targeting polypeptide radioactive medicine and preparation method and application thereof Download PDFInfo
- Publication number
- CN106581700A CN106581700A CN201611095338.5A CN201611095338A CN106581700A CN 106581700 A CN106581700 A CN 106581700A CN 201611095338 A CN201611095338 A CN 201611095338A CN 106581700 A CN106581700 A CN 106581700A
- Authority
- CN
- China
- Prior art keywords
- hylf8
- her2
- minutes
- novel polypeptide
- hynic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a novel HER2-targeting polypeptide radioactive medicine and a preparation method and an application thereof. The novel HER2-targeting polypeptide radioactive medicine includes an HYLF8 polypeptide and radionuclide 99mTc; the HYLF8 polypeptide is prepared by connecting a polypeptide YLFFVFER with a bifunctional chelating agent HYNIC, namely HYNIC-YLFFVFER; the radionuclide 99mTc labels the HYLF8 polypeptide through the bifunctional chelating agent HYNIC, and thus the novel HER2-targeting polypeptide radioactive medicine, namely 99mTc-HYLF8, is obtained; the novel HER2-targeting polypeptide radioactive medicine is a colorless transparent liquid injection.
Description
Technical field
The present invention relates to diagnosing tumor radiopharmaceutical, more particularly to a kind of novel polypeptide radiopharmaceutical of targeting HER2
And its preparation method and application.
Background technology
In worldwide, breast carcinoma still comes first of women's kinds of tumor, and mortality rate is located at second.Mesh
Before, the conventional methods for clinical diagnosis of breast carcinoma includes mammary X-ray photography, color ultrasound and MRI.These Imaging Methods and mammary gland tissue
Biopsy is compared, and with noninvasive advantage, but is also faced with low accuracy rate, shortage specificity, cannot be provided molecular level information
The shortcomings of.Used as the important mode of molecular imaging, PET and SPECT is clinically widely used.They the characteristics of
It is that sensitivity is high, and with accurate quantitative analysis and tumor-related molecules horizontal information can be provided.At present, clinically 25% ~ 30%
All there is the high expression of HER2 albumen in patients with breast cancer cell.The high expression of HER2 is often imply that with high transfer wind
Danger, Tumor Differentiation difference and prognosis be not good.With going deep into for studying to HER2, become mammary gland for the molecular targeted therapy of HER2
The important directions of cancer Therapy study.Herceptin（Trastuzumab, trastuzumab）It is that first, the whole world goes through to be applied to face
The specific humanized monoclonal antibodies of HER2 of bed.Trastuzumab energy specific effects are in the HER2 on breast cancer cell surface
Receptor, and induce immunocyte to kill tumor, the killing to normal cell is less, with high-affinity and targeting, is mammary gland
The representative drugs of cancer molecular targeted therapy.However, not all patient has response to the treatment of Trastuzumab,
Only the breast cancer patients of fraction can benefit from treatment.More seriously, most patient with breast cancer eventually exists
Produce drug resistance in Trastuzumab therapeutic processes, and the somewhat expensive of Trastuzumab immunization therapies, cycle are long.Therefore, build
Vertical new breast carcinoma HER2 targeting nucleus medical image method is for screening patient exactly, accurately monitor curative effect, reasonably
Arrange therapeutic scheme, effectively carry out prognostic evaluation finally to realize that individualized treatment is significant.
The content of the invention
Object of the present invention is to provide a kind of novel polypeptide radiopharmaceutical of targeting HER2, the medicine is by double work(
Can chelating agen by radionuclide99mTc is tagged on HYLF8 peptide molecules, in vivo target of the labeled drug by HYLF8 polypeptides
Gather tumor locus to effect is dense, using the single photon tomography technology of nuclear medicine, imaging is carried out to HER2 positive tumors and is examined
It is disconnected.
The purpose of the present invention is achieved through the following technical solutions：
A kind of novel polypeptide radiopharmaceutical of targeting HER2, including HYLF8 polypeptides and radionuclide99mTc, the HYLF8
Polypeptide is to be connected polypeptide YLFFVFER with bifunctional chelating agent HYNIC, i.e. HYNIC-YLFFVFER；The radionuclide99mTc obtains the novel polypeptide radioactivity of the targeting HER2 by HYLF8 polypeptides described in bifunctional chelating agent HYNIC labellings
Medicine, i.e.,99mThe novel polypeptide radiopharmaceutical of Tc-HYLF8, the targeting HER2 is colourless transparent liquid injection.
The radiopharmaceutic preparation method of novel polypeptide of described targeting HER2, comprises the following steps：
The preparation of a, HYNIC-YLFFVFER
SBz-HYNIC and Fmoc-YLFFVFER polypeptides are dissolved in DMF, pH value are adjusted with DIEA (DIPEA)
To 8.5-9.0, it is stirred overnight at room temperature；Piperidines is added to make final concentration of 20%, room temperature reaction 10 minutes, the product Jing YMC- for obtaining
Pack ODS-A semi-preparative column HPLC are isolated and purified, and collect the fraction of object, merge collection liquid lyophilizing, obtain described
HYLF8 linear polypeptides, i.e. HYNIC-YLFFVFER；
b、99mThe preparation of Tc-HYLF8
1）Prepare the mixed liquor of sodium trisulfonate containing triphenylphosphine, trihydroxy methyl glycine, disodium succinate, succinic acid and HYLF8
500 μ L add the radioactivity of 1.0-1.5 mL in the Na of 10 ~ 50 mCi in 10 mL cillin bottles99mTcO4Solution,
100 DEG C of heating in water bath cillin bottles react 20 ~ 25 minutes, and question response terminates rear room temperature and cools down 10 minutes, makes described targeting
The novel polypeptide radiopharmaceutical of HER2, i.e.,99mTc-HYLF8；
Further, sodium trisulfonate containing triphenylphosphine described in step b, trihydroxy methyl glycine, disodium succinate, succinic acid and
In the mixed liquor of HYLF8, the content of each material is：
5.0 mg of triphenylphosphine sodium trisulfonate
6.5 mg of trihydroxy methyl glycine
38.5 mg of disodium succinate
12.7 mg of succinic acid
HYLF8 20 μg。
Further, HPLC methods described in step b are to be equipped with YMC-Pack using 1260 HPLC systems of Agilent
ODS-A semi-preparative columns, gradient elution 35 minutes, wherein 4 mL/min of flow velocity, mobile phase A are H2O, B are acetonitrile, drip washing gradient
It is set as 100% A, 50% A and 50% B when 15 minutes during 0-5 minutes, 30% A and 70% B, 50% A when 30 minutes when 25 minutes
With 50% B, 100% A when 35 minutes.
The radiopharmaceutic application of novel polypeptide of described targeting HER2, the novel polypeptide radioactivity of the targeting HER2
Medicine can be used for the radiopharmaceutical for preparing HER2 positive tumor localization diagnosises.
Further, the HER2 positive tumors include breast carcinoma, cancer of pancreas, rectal cancer, gastric cancer.
The present invention having the beneficial effect that compared to existing technology：
1st, the present invention used in HYNIC as bifunctional chelating agent, while use tricine (trihydroxy methyl glycine) and
TPPTS (trisodium triphenylphosphine- 3,3', 3''-trisulfonate, triphenylphosphine sodium trisulfonate)
As synergy modes so that "99mTc-HYNIC cores " are with better internal external stability；
2nd, the HYLF8 polypeptides of targeting HER2 have good HER2 Targeting Performances, can effectively tell different tumor cells
HER2 expressions.It should be noted that HYLF8 is different from the HER2 binding sites of Herceptin so which has reality
When monitor Herceptin therapeutic process in HER2 situation of change, and will not be subject to excess Herceptin be affected.This
The treatment of Herceptin can be effectively instructed, is that the accurate medication of patient with breast cancer plays a key effect；
3rd, the novel polypeptide radiopharmaceutical of targeting HER2 of the present invention, can be applicable to the imaging of HER2 positive tumor patients
Diagnosis, and to receiving the monitoring and therapeutic evaluation of cancer therapy drug Trastuzumab treatment patients.
Description of the drawings
Fig. 1 be HYLF8 and its99mTc tag structure schematic diagrams；
Fig. 2 is99mInternal distribution results of the Tc-HYLF8 in MDA-MB-453 breast carcinoma BALB/c nude mice models；
Fig. 3 is injection99mThe SPECT imaging figures of MDA-MB-453 cancer of pancreas BALB/c nude mice models after Tc-HYLF8.
Specific embodiment
Material employed in the embodiment of the present invention：succinic acid（Succinic acid）、disodium succinate
hexahydrate （Disodium succinate）、trisodium triphenylpheosphine-3,3',3''-trisulfonate
（TPPTS, triphenylphosphine sodium trisulfonate）、N,N-Dimethylform amide（DMF, DMF）、tricine
（Trihydroxy methyl glycine）It is purchased from Sigma-Aldrich.YLFFVFER polypeptide monomers are purchased from China CSBio
Ltd. company.Na99mTcO4Eluent is purchased from Beijing Atom High Tech Co., Ltd..
The present embodiment with the novel polypeptide radiopharmaceutical of targeting HER2, i.e.,99mTc-HYLF8 polypeptide radiopharmaceuticals and its
As a example by preparation method.
The novel polypeptide radiopharmaceutical of the targeting HER2, including HYLF8 polypeptides and radionuclide99mTc.It is described to put
Penetrating property nucleic99m, by HYLF8 polypeptides described in difunctional chelation group HYNIC labellings, the HYLF8 linear polypeptides are will be more for Tc
P277 LFFVFER is connected with bifunctional chelating agent HYNIC, i.e. HYNIC-YLFFVFER, described99mTc-HYLF8 polypeptide radioactivity medicines
Thing is colourless transparent liquid injection.
The radiopharmaceutic preparation method of novel polypeptide of the targeting HER2 is as follows：
A. the preparation of YLFFVFER-HYNIC：SBz-HYNIC and Fmoc-YLFFVFER polypeptides are dissolved in DMF, are adjusted with DIEA
Section pH value is stirred overnight at room temperature to 8.5-9.0；Piperidines is added to make final concentration of 20%, room temperature reaction 10 minutes.Product Jing YMC-
Pack ODS-A semi-preparative column HPLC are isolated and purified, and collect the fraction of object, merge collection liquid lyophilizing.
b. 99mThe preparation of Tc-HYLF8：Sodium trisulfonate containing triphenylphosphine (TPPTS) 5.0 mg is prepared, trihydroxy methyl is sweet
Propylhomoserin（tricine）The mixed liquor 500 of the HYLF8 of 6.5 mg, 38.5 mg of disodium succinate, 12.7 mg of succinic acid and 20 μ g
μ L add the Na of 1.0-1.5 mL in 10 mL cillin bottles99mTcO4Solution（10~50 mCi）, 100 °C of heating in water bath XiLin
Bottle reaction 20 ~ 25 minutes, question response terminate rear room temperature and cool down 10 minutes, make the novel polypeptide radiopharmaceutical of targeting HER2.
HYLF8 polypeptide radiopharmaceuticals 99mTc-HYLF8 samplings to preparing according to the inventive method carry out radioactivity
HPLC is analyzed（Using 1260 HPLC systems of Agilent, radioactivity on-line checking device and YMC-Pack ODS-A C18 point are equipped with
Analysis post（4.6 mm × 250 mm, 300pore size）, gradient elution 35 minutes, 1.0 mL/min of flow velocity.Wherein flow
Phase A is H2O, and B is acetonitrile.Drip washing gradient is set as 100% A, 50% A and 50% B when 15 minutes, when 25 minutes during 0-5 minutes
30% A and 70% B, 50% A and 50% B, 100% A when 35 minutes when 30 minutes.
Claims (6)
1. a kind of novel polypeptide radiopharmaceutical of targeting HER2, including HYLF8 polypeptides and radionuclide99mTc, its feature exist
In the HYLF8 polypeptides are to be connected polypeptide YLFFVFER with bifunctional chelating agent HYNIC, i.e. HYNIC-YLFFVFER；It is described
Radionuclide99mTc obtains the new of the targeting HER2 by HYLF8 polypeptides described in bifunctional chelating agent HYNIC labellings
Polypeptide radiopharmaceutical, i.e.,99mThe novel polypeptide radiopharmaceutical of Tc-HYLF8, the targeting HER2 is colourless transparent liquid pin
Agent.
2. a kind of radiopharmaceutic preparation method of novel polypeptide of targeting HER2 as claimed in claim 1, it is characterised in that
The method comprising the steps of：
The preparation of a, HYNIC-YLFFVFER
SBz-HYNIC and Fmoc-YLFFVFER polypeptides are dissolved in DMF, pH value are adjusted to 8.5-9.0 with DIEA, are stirred at room temperature
Overnight；Piperidines is added to make final concentration of 20%, room temperature reaction 10 minutes, the product Jing YMC-Pack ODS-A semi-preparative columns for obtaining
HPLC is isolated and purified, and collects the fraction of object, merges collection liquid lyophilizing, obtains described HYLF8 linear polypeptides, i.e.,
HYNIC-YLFFVFER；
b、99mThe preparation of Tc-HYLF8
1）Prepare the mixed liquor of sodium trisulfonate containing triphenylphosphine, trihydroxy methyl glycine, disodium succinate, succinic acid and HYLF8
500 μ L add the radioactivity of 1.0-1.5 mL in the Na of 10 ~ 50 mCi in 10 mL cillin bottles99mTcO4Solution,
100 DEG C of heating in water bath cillin bottles react 20 ~ 25 minutes, and question response terminates rear room temperature and cools down 10 minutes, makes described targeting
The novel polypeptide radiopharmaceutical of HER2, i.e.,99mTc-HYLF8。
3. the radiopharmaceutic preparation method of novel polypeptide of targeting HER2 according to claim 2, it is characterised in that step
In the mixed liquor of sodium trisulfonate containing triphenylphosphine, trihydroxy methyl glycine, disodium succinate, succinic acid and HYLF8 described in rapid b,
The content of each material is：
5.0 mg of triphenylphosphine sodium trisulfonate
6.5 mg of trihydroxy methyl glycine
38.5 mg of disodium succinate
12.7 mg of succinic acid
HYLF8 20 μg。
4. the radiopharmaceutic preparation method of novel polypeptide of targeting HER2 according to claim 2, it is characterised in that step
HPLC methods described in rapid b are to be equipped with YMC-Pack ODS-A semi-preparative columns, gradient elution using 1260 HPLC systems of Agilent
35 minutes, 4 mL/min of flow velocity, wherein mobile phase A were H2O, B are acetonitrile, and drip washing gradient is set as 100% A during 0-5 minutes,
50% A and 50% B when 15 minutes, 30% A and 70% B when 25 minutes, 50% A and 50% B when 30 minutes, 100% when 35 minutes
A。
5. a kind of radiopharmaceutic application of novel polypeptide of targeting HER2 as claimed in claim 1, it is characterised in that described
The novel polypeptide radiopharmaceutical of targeting HER2 can be used for the radiopharmaceutical for preparing HER2 positive tumor localization diagnosises.
6. the radiopharmaceutic application of novel polypeptide of targeting HER2 according to claim 5, it is characterised in that described
HER2 positive tumors include breast carcinoma, cancer of pancreas, rectal cancer, gastric cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611095338.5A CN106581700B (en) | 2016-12-02 | 2016-12-02 | A kind of novel polypeptide radiopharmaceutical for targeting HER2 and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611095338.5A CN106581700B (en) | 2016-12-02 | 2016-12-02 | A kind of novel polypeptide radiopharmaceutical for targeting HER2 and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106581700A true CN106581700A (en) | 2017-04-26 |
| CN106581700B CN106581700B (en) | 2018-05-18 |
Family
ID=58596451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611095338.5A Active CN106581700B (en) | 2016-12-02 | 2016-12-02 | A kind of novel polypeptide radiopharmaceutical for targeting HER2 and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581700B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045313A (en) * | 2018-09-11 | 2018-12-21 | 北京大学 | A kind of D-type polypeptide radiopharmaceutical and preparation method targeting HER2 |
| WO2020063216A1 (en) * | 2018-09-28 | 2020-04-02 | 京东方科技集团股份有限公司 | Peptoid compound and preparation method therefor, oligomer, pharmaceutical composition and kit |
| CN111991570A (en) * | 2020-07-24 | 2020-11-27 | 北京大学 | FAP-alpha specific tumor diagnosis SPECT imaging agent |
| CN112358531A (en) * | 2020-11-09 | 2021-02-12 | 国家纳米科学中心 | Polypeptide targeting HER2 protein and application thereof |
| CN114456227A (en) * | 2022-01-19 | 2022-05-10 | 北京师范大学 | Technetium-99 m labeled D-proline-containing glycine polypeptide modified FAPI derivative, and preparation method and application thereof |
| WO2024017317A1 (en) * | 2022-07-20 | 2024-01-25 | 中国科学院上海药物研究所 | Her2 targeting peptide molecule and use thereof |
-
2016
- 2016-12-02 CN CN201611095338.5A patent/CN106581700B/en active Active
Non-Patent Citations (5)
| Title |
|---|
| CALZADA V，等: "Labeling and Biological Evaluation of (99m)Tc-HYNICTrastuzumab as a Potential Radiopharmaceutical for In Vivo Evaluation of HER2 Expression in Breast Cancer", 《WORLD J NUCL MED》 * |
| JIA X，等: "Micromixer Based Preparation of Functionalized Liposomes and Targeting Drug Delivery", 《ACS MED CHEM LETT》 * |
| JIYUN SHI，等: "A Novel 99mTc-labeled isoDGR Peptide for Integrin αvβ6/α5β1 Bi-selectively Targeted NanoSPECT/CT Imaging of Pancreatic Cancer", 《J NUCL MED》 * |
| WANG Z，等: "Microarray based screening of peptide nano probes for HER2 positive tumor", 《ANAL CHEM》 * |
| ZHAO H，等: "(99m)Tc-HisoDGR as a Potential SPECT Probe for Orthotopic Glioma Detection via Targeting of Integrin α5β1", 《 BIOCONJUG CHEM》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045313A (en) * | 2018-09-11 | 2018-12-21 | 北京大学 | A kind of D-type polypeptide radiopharmaceutical and preparation method targeting HER2 |
| CN109045313B (en) * | 2018-09-11 | 2020-02-18 | 北京大学 | D-type polypeptide radiopharmaceutical targeting HER2 and preparation method thereof |
| WO2020063216A1 (en) * | 2018-09-28 | 2020-04-02 | 京东方科技集团股份有限公司 | Peptoid compound and preparation method therefor, oligomer, pharmaceutical composition and kit |
| US11591370B2 (en) | 2018-09-28 | 2023-02-28 | Beijing Boe Technology Development Co., Ltd. | Peptoid compound and manufacturing method thereof, oligomer, pharmaceutical composition, and kit |
| CN111991570A (en) * | 2020-07-24 | 2020-11-27 | 北京大学 | FAP-alpha specific tumor diagnosis SPECT imaging agent |
| WO2022017375A1 (en) * | 2020-07-24 | 2022-01-27 | 北京大学 | SPECT CONTRAST AGENT FOR FAP-α-SPECIFIC TUMOR DIAGNOSIS |
| CN112358531A (en) * | 2020-11-09 | 2021-02-12 | 国家纳米科学中心 | Polypeptide targeting HER2 protein and application thereof |
| CN112358531B (en) * | 2020-11-09 | 2022-05-27 | 国家纳米科学中心 | Polypeptide targeting HER2 protein and application thereof |
| CN114456227A (en) * | 2022-01-19 | 2022-05-10 | 北京师范大学 | Technetium-99 m labeled D-proline-containing glycine polypeptide modified FAPI derivative, and preparation method and application thereof |
| CN114456227B (en) * | 2022-01-19 | 2023-03-21 | 北京师范大学 | Technetium-99 m labeled D-proline-containing glycine polypeptide modified FAPI derivative, and preparation method and application thereof |
| WO2024017317A1 (en) * | 2022-07-20 | 2024-01-25 | 中国科学院上海药物研究所 | Her2 targeting peptide molecule and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106581700B (en) | 2018-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106581700B (en) | A kind of novel polypeptide radiopharmaceutical for targeting HER2 and its preparation method and application | |
| CN111592584B (en) | HER2 affinity body and diagnosis and treatment nuclide marker as well as preparation method and application thereof | |
| Granov et al. | Positron emission tomography | |
| Gao et al. | A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients | |
| CN105126128B (en) | A kind of tumour VEGFR-3 molecular imagings agent and its application | |
| CN113583089B (en) | Tumor PD-L1 targeted PET imaging agent, labeling precursor, preparation method and application thereof | |
| CN112851637B (en) | PSMA inhibitor, compound, preparation method and application thereof | |
| CN111840585B (en) | Pharmaceutical composition for tumor immunotherapy | |
| CN108434468A (en) | A kind of protein binding partner of radioiodination and its application | |
| CN104725473A (en) | [<18>F] AlF marked positron emission tomography (PET) polypeptide probe and preparation method thereof | |
| CN112043839A (en) | Radioisotope-labeled polypeptide imaging agent targeting transferrin receptor and application thereof | |
| WO2020238795A1 (en) | Rk polypeptide radiopharmaceutical targeting her2, and preparation method therefor | |
| CN110420337A (en) | A kind of targeted integration element α6Dimer polypeptide radiopharmaceutical and preparation method thereof | |
| CN109045313A (en) | A kind of D-type polypeptide radiopharmaceutical and preparation method targeting HER2 | |
| Guo et al. | Development of 99mTc-conjugated JS001 antibody for in vivo mapping of PD-1 distribution in murine | |
| Stahl et al. | PET/CT molecular imaging in abdominal oncology | |
| CN108434469A (en) | A kind of HER2 affinities body68Ga markers and preparation method thereof, application | |
| CN106492237B (en) | A kind of isoDGR polypeptide radiopharmaceuticals and its preparation method and application | |
| Sharma et al. | Lat-1 based primary breast cancer detection by [99m] tc-labeled dtpa-bis-methionine scintimammography: First results using indigenously developed single vial kit preparation | |
| CN115286693A (en) | Tumor targeting peptide aiming at carcinoembryonic antigen related cell adhesion molecule CEACAM6 and application thereof | |
| CN107496943A (en) | The preparation method for the Dimer San A Cyclopeptide derivatives cancer of pancreas molecular probes that F 18 is marked | |
| CN108144073A (en) | Target the three polyethyleneglycol modified duramycin polypeptide drugs of radioactive label of phosphatidyl-ethanolamine | |
| CN102861347B (en) | 99mTc labeling galactosed arginyl-glycyl-aspartic acid (RGD) tumor diagnosis medicine and preparation method | |
| CN103330951B (en) | Novel VQ polypeptide radioactive medicine and preparation method thereof | |
| CN107674117A (en) | The preparation method for the Dimer San A Cyclopeptide derivatives cancer of pancreas molecular probes that Cu 64 is marked |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |